About Us

Caring Through Science & Technology

Overview

Our Vision

Honors and Milestones

Global Footprints

Honors and Milestones

ABOUT US

Overview

Our Vision

Honors and Milestones

Global Footprints

Honors and Milestone

5 TOP

Chinese pharmaceutical companies

5 TOP

Most innovative Chinese pharmaceutical companies

10 TOP

Exporting member enterprises of the Chinese Industrial Association of Generic Drugs

Leading enterprise for formulation internationalization

Chinese National Engineering Laboratory for Mammalian Cell High Expression

Chinese National Engineering Laboratory for Innovative Liposome and Microsphere Formulations

Milestone

2024

Biosimilar Ranibizumab injection approved in EU .

2023

"First-to-Launch" generic Octreotide LAI, Paliperidone Palmitate LAI, and biosimilar Aflibercept injection in China.

2023

"First-to-Launch" Gefitinib generic in US.

2023

Cisplatin Inj supplied to US for national drug shortage.

2023

1st innovative drug (Iruplinalkib) approved and launched in China.

2022

"First-to-Launch“ Cefazolin for injection 2g in US.

2021

1st company to launch rFSH Biosimilar in China.

2019

1st company to launch Bevacizumab Biosimilar in China

2016

Injectables exported to US

2015

Chinese company to export packaged injectables to Japan; Injectables exported to EU

2014

Sales revenue reached 10+ billion CNY (USD $1.4 bllion)

2012

Injectables exported to Australia

2010

1st Chinese company to obtain USFDA approval for sterile APIs

2004

1st Chinese company to obtain EDQM approval for sterile APIs

2003

Transformed into a shareholding cooperation.

1999

G-CSF launched in China

1990

Sales revenue reached 100 million CNY (USD $14 million)

1982

Ampicillin Sodium for Injection launched in China

1958

Founded in Jinan, China as a state-owned company.

Tel: +86-531-83127705, 83127704, 83127706, 83127711

Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China

E mail：export@qilu-pharma.com, FDF@qilu-pharma.com

监督举报

亲爱的合作伙伴：

欢迎举报以下行为！

索贿、暗箱操纵招标、内定中标单位、员工或亲属参与公司业务往来牟取私利、偷工减料、以次充好、故意刁难供应商等行为。

举报电话：0531-83126898/55820713/83126871

举报邮箱：qljc@qilu-pharma.com

收信地址：山东省济南市历城区旅游路8888号

齐鲁制药集团审计监察部

采购平台技术专线

0531-55820865